Product Name: Zilucoplan Sodium
CAS No: 1841136-73-9
Purity: 95%
Molar Mass: 3562.18
Chemical Formula: C172H278N24O55
Synonyms: RA101495
Storage: Store at -20℃
Target: complement component 5
Application: Zilucoplan sodium (CAS: 1841136-73-9) is a synthetic peptide-based inhibitor of complement component 5 (C5), a key protein in the complement cascade involved in immune response regulation. Zilucoplan functions by binding to C5 and preventing its cleavage into C5a and C5b, thereby inhibiting the formation of the membrane attack complex (MAC) and downstream inflammatory responses mediated by C5a. This inhibition helps to mitigate excessive complement activation, which is implicated in the pathogenesis of various autoimmune diseases, particularly neuromuscular disorders such as myasthenia gravis. Zilucoplan sodium is being investigated for its potential in the treatment of myasthenia gravis, offering a targeted approach to modulating the dysregulated immune response underlying this condition. In pharmaceutical chemistry, zilucoplan sodium’s specific inhibition of C5 represents a promising advancement in autoimmune disease therapy, providing a novel therapeutic option for patients with myasthenia gravis who may not respond adequately to conventional immunosuppressive treatments. Ongoing clinical trials aim to further evaluate its safety, efficacy, and long-term outcomes, with the goal of improving disease management and quality of life for individuals with myasthenia gravis.
Reference:
